ClinicalTrials.gg
Active, not recruitingNCT03777631STABLEDUpdated Nov 15, 2023

STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study

A Phase 3 interventional study of Catheter ablation in Ischemic Stroke and Atrial Fibrillation Non-Rheumatic, sponsored by Nippon Medical School. Active, not recruiting at 46 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Nippon Medical School · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 7 months after the study started (first participant enrolled Apr 2018, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Enrollment
19th of 35
251 · median 270
Started
2018
with 3 others
Phase 3
8 of 43
none open now
Primary completion
2026-03
later than 1 of 10 live
Registered
25th of 43
by date
Lead sponsor
2 of 43
Nippon Medical School

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 19th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucidated in NVAF with recent cerebral infarction in prospective randomized trials.

Read the detailed description

In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the reported annual recurrence rate in NVAF and previous stroke patients in the "real-world" is not low even with appropriate antithrombotic treatment; 8.6% in patients with "guideline adherent" antithrombotic therapy and around 5% in patients treated with anticoagulant therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent task.

Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some retrospective studies showed a beneficial effect of CA for stroke prevention using age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve survival or prevent heart failure development in patients with AF. However, the effect of CA for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke for survival or developing heart failure has not been evaluated in a prospective randomized trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF with a history of cerebral infarction: a group receiving standard medical therapy (control group) and a group receiving standard medical therapy plus CA (CA group).

03

Conditions studied

  • Ischemic Stroke
  • Atrial Fibrillation Non-Rheumatic

Browse trials for

Keywords

  • anticoagulation treatment
  • catheter ablation
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥20 or ≤85 years at time of giving
  • Nonvalvular atrial fibrillation
  • History of stroke in previous 6 months
  • Current or planned treatment with edoxaban
  • Modified Rankin scale ≤3

Exclusion criteria

Exclusion Criteria:

  • Symptomatic paroxysmal AF resistant to anti-arrhythmic drugs
  • Presence of left atrial thrombus and left atrial appendage on transthoracic echocardiography, computed tomography or magnetic resonance imaging
  • Unable to take anticoagulation therapy for any reason, including tendency to bleed or considered at high risk for bleeding from anticoagulation therapy.
  • Presence of severe renal disorder (estimated \<30 mL/min by Cockroft-Gault equation)
  • Previous CA or surgical intervention for AF
  • History of treatment with a left atrial appendage closure device
  • Left atrial diameter ≥55 mm on transthoracic echocardiography
  • ≤35% on transthoracic echocardiography
  • Persistent AF for ≥10 years
  • Pregnant or possibility of pregnancy
  • Unlikely to complete the study, such as due to progressive malignant tumor
  • Participating or planning to participate in another clinical trial
  • Unwilling to participates
  • Judged as incompatible for the study by the investigators
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • No intervention
    Standard medical therapy group

    The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.

  • Active comparator
    Catheter ablation group

    Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed \>100 CA annually were participated in the present study in principle.

    Procedure: Catheter ablation

Interventions

  • ProcedureCatheter ablation

    CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.

06

What researchers measure

Primary outcomes

  1. Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.

    Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.

    Time frame: Up to 6 years

Secondary outcomes

  1. Recurrence of cerebral infarction

    Recurrence of cerebral infarction

    Time frame: Up to 6 years

  2. Systemic embolism

    Symptomatic systemic embolism to other regions than brain, e.g. peripheral or visceral arteries

    Time frame: Up to 6 years

  3. All-cause death

    All-cause death

    Time frame: Up to 6 years

  4. Cardiovascular death

    Cardiovascular death

    Time frame: Up to 6 years

  5. Hospitalization for heart failure

    Hospitalization for heart failure

    Time frame: Up to 6 years

  6. Any bleeding

    Any bleeding

    Time frame: Up to 6 years

  7. Intracranial hemorrhage

    Intracranial hemorrhage

    Time frame: Up to 6 years

  8. Composite events

    all-cause death, onset of stroke, systemic embolism, hospitalization for heart failure, and serious adverse event caused by CA

    Time frame: Up to 6 years

  9. The rate of and related factors to discontinuation of Edoxaban

    The rate of and related factors to discontinuation of Edoxaban

    Time frame: Up to 6 years

  10. Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban

    Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban

    Time frame: Up to 6 years

Other outcomes

  1. Incidence of treatment-emergent adverse events (safety and tolerability)

    Incidence of treatment-emergent adverse events (safety and tolerability)

    Time frame: Within 1 month after CA

  2. Incidence of all adverse events, not restricted to CA maneuver-related adverse events

    Incidence of all adverse events, not restricted to CA maneuver-related adverse events

    Time frame: Within 1 month after CA

  3. Drug reaction to edoxaban

    Drug reaction to edoxaban

    Time frame: Up to 6 years

07

Study locations

46 sites
08

References and documents

Publications

  • Sakamoto Y, Nishiyama Y, Iwasaki YK, Daida H, Toyoda K, Kitagawa K, Okumura K, Kusano K, Hagiwara N, Fujimoto S, Miyamoto S, Otsuka T, Iguchi Y, Kanamaru T, Yamamoto T, Kaburagi J, Kimura T, Matsumoto T, Kimura K, Shimizu W; STABLED Study Investigators. Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study. J Cardiol. 2019 Dec;74(6):539-542. doi: 10.1016/j.jjcc.2019.06.002. Epub 2019 Jul 20. PubMed 31337525 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Mar 2026, 95 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 95 months is above that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2018
First posted
Dec 17, 2018
StartActual
Apr 1, 2018
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03777631
Lead sponsor
Nippon Medical School
Responsible party
Kazumi Kimura (Professor, Nippon Medical School) — Principal investigator
First posted
Dec 17, 2018
Start date
Apr 1, 2018
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Nov 15, 2023

Study contacts

Kazumi Kimura, M.D., Ph.D
principal investigator · Department of Neurology, Nippon Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion